Use of cidofovir in pediatric patients with adenovirus infection [version 1; referees: 2 approved]
Background: Adenoviruses contribute to morbidity and mortality among immunocompromised pediatric patients including stem cell and solid organ transplant recipients. Cidofovir (CDV), an antiviral compound approved by the FDA in 1996, is used for treatment of adenoviral (ADV) infections in immunocompr...
Main Authors: | Lakshmi Ganapathi, Alana Arnold, Sarah Jones, Al Patterson, Dionne Graham, Marvin Harper, Ofer Levy |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2016-04-01
|
Series: | F1000Research |
Subjects: | |
Online Access: | http://f1000research.com/articles/5-758/v1 |
Similar Items
-
Pediatric hereditary angioedema: an update [version 1; referees: 2 approved]
by: Geetika Sabharwal, et al.
Published: (2017-07-01) -
Mechanisms of pathogenesis of emerging adenoviruses [version 1; referees: 2 approved]
by: James Cook, et al.
Published: (2017-01-01) -
Drug-Induced Metabolic Acidosis [version 1; referees: 3 approved]
by: Amy Quynh Trang Pham, et al.
Published: (2015-12-01) -
Recent advances in understanding and treating ARDS [version 1; referees: 2 approved]
by: Rebecca M. Baron, et al.
Published: (2016-04-01) -
Creutzfeldt-Jakob disease: recent developments [version 1; referees: 2 approved]
by: Graeme Mackenzie, et al.
Published: (2017-11-01)